EUVIMEDEUVIMED entdecken
Open Access

Structural pharmacology and therapeutic potential of 5-methoxytryptamines

Audrey L Warren iD, David Lankri iD, Michael J Cunningham, Inis C Serrano iD, Lyonna F Parise iD, Andrew C Kruegel, Priscilla Duggan iD, Gregory Zilberg, Michael J Capper iD, Vaclav Havel iD, Scott J Russo iD, Dalibor Sames iD und 1 weitere

Nature · 06.06.2024 · 630 (8015) · 237-246

DOI: 10.1038/s41586-024-07403-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature, online erschienen am 08.05.2024. Verfasst von Audrey L Warren und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: 5-Methoxytryptamine, Anti-Anxiety Agents, Antidepressive Agents, Methoxydimethyltryptamines. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NIDA NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders1-3. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT2A (ref. 4). However, 5-HT1A also plays a part in the behavioural effects of tryptamine hallucinogens5, particularly 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a psychedelic found in the toxin of Colorado River toads6. Although 5-HT1A is a validated therapeutic target7,8, little is known about how psychedelics engage 5-HT1A and which effects are mediated by this receptor. Here we map the molecular underpinnings of 5-MeO-DMT pharmacology through five cryogenic electron microscopy (cryo-EM) structures of 5-HT1A, systematic medicinal chemistry, receptor mutagenesis and mouse behaviour. Structure-activity relationship analyses of 5-methoxytryptamines at both 5-HT1A and 5-HT2A enable the characterization of molecular determinants of 5-HT1A signalling potency, efficacy and selectivity. Moreover, we contrast the structural interactions and in vitro pharmacology of 5-MeO-DMT and analogues to the pan-serotonergic agonist LSD and clinically used 5-HT1A agonists. We show that a 5-HT1A-selective 5-MeO-DMT analogue is devoid of hallucinogenic-like effects while retaining anxiolytic-like and antidepressant-like activity in socially defeated animals. Our studies uncover molecular aspects of 5-HT1A-targeted psychedelics and therapeutics, which may facilitate the future development of new medications for neuropsychiatric disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5-MethoxytryptamineAnti-Anxiety AgentsAntidepressive AgentsMethoxydimethyltryptaminesReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2AAnimalsHumansMaleMiceCryoelectron MicroscopyHallucinogensLysergic Acid DiethylamideModels, MolecularSerotonin Receptor AgonistsStructure-Activity Relationship

Substanzen

5-MethoxytryptamineAnti-Anxiety AgentsAntidepressive AgentsHallucinogensLysergic Acid DiethylamideMethoxydimethyltryptaminesReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2ASerotonin Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Chemistry, Columbia University, New York, NY, USA.
  • Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Zuckerman Institute of Mind, Brain, Behavior, Columbia University, New York, NY, USA.
  • Department of Chemistry, Columbia University, New York, NY, USA. ds584@columbia.edu.
  • Zuckerman Institute of Mind, Brain, Behavior, Columbia University, New York, NY, USA. ds584@columbia.edu.

ORCID-Profile: Audrey L Warren, David Lankri, Inis C Serrano, Lyonna F Parise, Priscilla Duggan, Michael J Capper, Vaclav Havel, Scott J Russo, Dalibor Sames, Daniel Wacker

Förderung

  • NIMH NIH HHS
  • NIDA NIH HHS
  • NIGMS NIH HHS
  • NIH HHS

Zitieren

APA

Warren, A. L., Lankri, D., Cunningham, M. J., Serrano, I. C., Parise, L. F., Kruegel, A. C., Duggan, P., Zilberg, G., Capper, M. J., Havel, V., Russo, S. J., Sames, D., & Wacker, D. (2024). Structural pharmacology and therapeutic potential of 5-methoxytryptamines. Nature, 630(8015), 237-246. https://doi.org/10.1038/s41586-024-07403-2

Vancouver

Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, et al. Structural pharmacology and therapeutic potential of 5-methoxytryptamines. Nature. 2024;630(8015):237-246. doi:10.1038/s41586-024-07403-2

BibTeX
@article{Warren2024,
  author = {Warren, Audrey L and Lankri, David and Cunningham, Michael J and Serrano, Inis C and Parise, Lyonna F and Kruegel, Andrew C and Duggan, Priscilla and Zilberg, Gregory and Capper, Michael J and Havel, Vaclav and Russo, Scott J and Sames, Dalibor and Wacker, Daniel},
  title = {Structural pharmacology and therapeutic potential of 5-methoxytryptamines},
  journal = {Nature},
  year = {2024},
  volume = {630},
  number = {8015},
  pages = {237--246},
  doi = {10.1038/s41586-024-07403-2}
}
Kostenlos starten →